Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Shah SIA, Wilson HCP, Abel PD.

Nat Rev Urol. 2017 Sep;14(9):1. doi: 10.1038/nrurol.2017.126. Epub 2017 Aug 8. No abstract available.

2.

Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, Kanaga-Sundaram S, Dixit S, Laniado M, Madaan S, Collins G, Pope A, Welland A, Nankivell M, Wassersug R, Parmar MK, Langley RE, Abel PD.

BJU Int. 2017 May;119(5):667-675. doi: 10.1111/bju.13687. Epub 2016 Nov 12.

3.
4.

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, Scrase CD, Robertson A, Cafferty F, Welland A, Carpenter R, Honeyfield L, Abel RL, Stone M, Parmar MK, Abel PD.

Eur Urol. 2016 Jun;69(6):1016-25. doi: 10.1016/j.eururo.2015.11.030. Epub 2015 Dec 17.

5.
6.

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture.

Wilson HC, Shah SI, Abel PD, Price P, Honeyfield L, Edwards S, Abel RL.

Cent European J Urol. 2015;68(2):165-8. doi: 10.5173/ceju.2015.513. Epub 2015 Apr 20. Review.

7.

Parenteral oestrogen: effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?

Shah SI, Abel PD, Duong T, Price P, Langley R.

Scand J Urol. 2014 Aug;48(4):411-2. doi: 10.3109/21681805.2014.925500. Epub 2014 Jun 2. No abstract available.

PMID:
24882276
8.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shah SI, Langley RE, Cafferty FH, Abel RL, Abel PD.

BJU Int. 2013 Nov;112(7):E431-2. doi: 10.1111/bju.12375. No abstract available.

9.

Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.

Shah SI, Cafferty FH, Langley RE, Abel PD.

J Sex Med. 2014 Jan;11(1):314-5. doi: 10.1111/jsm.12330. Epub 2013 Sep 25. No abstract available.

PMID:
24112553
10.

Extending the case for oestradiol in androgen-sensitive prostate cancer - Authors' reply.

Langley R, Cafferty FH, Abel PD.

Lancet Oncol. 2013 Jun;14(7):e253. doi: 10.1016/S1470-2045(13)70203-1. No abstract available.

PMID:
23725707
11.

Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.

Shah SI, Abel PD, Langley RE, Cafferty FH.

Br J Cancer. 2013 May 28;108(10):2192-3. doi: 10.1038/bjc.2013.210. Epub 2013 Apr 30. No abstract available.

12.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD.

Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4.

13.

Use of transdermal estrogen in the management of advanced prostate cancer.

Cafferty FH, Langley RE, Abel PD.

Urol Oncol. 2013 Feb;31(2):279. doi: 10.1016/j.urolonc.2012.08.016. No abstract available.

PMID:
23465481
14.

Reproducibility of quantitative assessment of altered hepatic hemodynamics with dynamic contrast-enhanced ultrasound.

Gauthier TP, Muhammad A, Wasan HS, Abel PD, Leen EL.

J Ultrasound Med. 2012 Sep;31(9):1413-20.

PMID:
22922621
15.

Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.

Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH.

Ther Adv Urol. 2012 Aug;4(4):155-60. doi: 10.1177/1756287212447092.

16.

Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy.

Karavitakis M, Ahmed HU, Abel PD, Livni N, Hazell S, Winkler MH.

Prostate. 2012 Sep 15;72(13):1464-8. doi: 10.1002/pros.22498. Epub 2012 Feb 10.

PMID:
22328187
17.

Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer.

Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH.

J Endourol. 2012 May;26(5):503-8. doi: 10.1089/end.2011.0345. Epub 2012 Feb 8.

PMID:
22142404
18.

Focal therapy for prostate cancer: opportunities and uncertainties.

Karavitakis M, Winkler MH, Abel PD, Hazell S, Ahmed HU.

Discov Med. 2011 Sep;12(64):245-55. Review.

19.

Transrectal high-intensity focused ultrasonography is feasible as a new therapeutic option for advanced recurrent rectal cancer: report on the first case worldwide.

Monzon L, Wasan H, Leen E, Ahmed H, Dawson PM, Harvey C, Muhamed A, Hand J, Price P, Abel PD.

Ann R Coll Surg Engl. 2011 Sep;93(6):e119-21. doi: 10.1308/147870811X592458.

20.

Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.

Langley RE, Cafferty FH, Pollock PA, Price P, Abel PD.

J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22. No abstract available.

PMID:
21513954
21.

Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91.

Langley RE, Price P, Abel PD.

Eur Urol. 2011 Apr;59(4):e24-5; author reply e26. doi: 10.1016/j.eururo.2011.01.005. Epub 2011 Jan 14. No abstract available. Erratum in: Eur Urol. 2011 Jul;60(1):194.

PMID:
21255905
22.

Tumor focality in prostate cancer: implications for focal therapy.

Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH.

Nat Rev Clin Oncol. 2011 Jan;8(1):48-55. doi: 10.1038/nrclinonc.2010.190. Epub 2010 Nov 23. Review.

PMID:
21116296
23.

Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem.

Langley R, Price P, Pollock P, Abel PD.

BJU Int. 2010 Sep;106(5):726-7; author reply 727. doi: 10.1111/j.1464-410X.2010.09605_1.x. No abstract available.

24.

Survival of patients with bladder cancer from a UK hospital: a 10-year follow-up study.

Low VJ, Wang D, Abel PD.

BJU Int. 2010 Jun;105(12):1667-71. doi: 10.1111/j.1464-410X.2009.09071.x. Epub 2010 Jan 8.

25.

Long term androgen deprivation therapy in prostate cancer.

Ockrim JL, Abel PD.

BMJ. 2008 Sep 22;337:a1361. doi: 10.1136/bmj.a1361. No abstract available.

PMID:
18809586
26.

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M, Abel PD.

BJU Int. 2008 Aug;102(4):442-5. doi: 10.1111/j.1464-410X.2008.07583.x. Epub 2008 Apr 16.

27.

Design and development of a prototype endocavitary probe for high-intensity focused ultrasound delivery with integrated magnetic resonance imaging.

Wharton IP, Rivens IH, Ter Haar GR, Gilderdale DJ, Collins DJ, Hand JW, Abel PD, deSouza NM.

J Magn Reson Imaging. 2007 Mar;25(3):548-56.

PMID:
17279503
28.
29.

Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.

Ockrim JL, Lalani el-N, Kakkar AK, Abel PD.

J Urol. 2005 Aug;174(2):527-33; discussion 532-3.

PMID:
16006886
30.

Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.

Ockrim JL, Lalani EN, Abel PD.

J Urol. 2005 May;173(5):1829; author reply 1829-30. No abstract available.

PMID:
15821605
31.

Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer.

Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, Laniado ME, Carter SS, Abel PD.

J Urol. 2004 Dec;172(6 Pt 1):2203-7.

PMID:
15538232
32.

TFF2 (trefoil family factor2) inhibits apoptosis in breast and colorectal cancer cell lines.

Siu LS, Romanska H, Abel PD, Baus-Loncar M, Kayademir T, Stamp GW, Lalani el-N.

Peptides. 2004 May;25(5):855-63.

PMID:
15177882
33.

TFF1 is membrane-associated in breast carcinoma cell line MCF-7.

Siu LS, Romanska H, Abel PD, Kayademir T, Blin N, Stamp GW, Lalani el-N.

Peptides. 2004 May;25(5):745-53.

PMID:
15177868
34.

Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder.

Khan AA, Abel PD, Chaudhary KS, Gulzar Z, Stamp GW, Lalani EN.

Mol Pathol. 2003 Dec;56(6):353-61.

35.

Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Nightingale J, Chaudhary KS, Abel PD, Stubbs AP, Romanska HM, Mitchell SE, Stamp GW, Lalani el-N.

Neoplasia. 2003 Jul-Aug;5(4):347-61. doi: 10.1016/S1476-5586(03)80028-3.

36.

Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD.

J Urol. 2003 May;169(5):1735-7.

PMID:
12686820
37.

Female urinary genuine stress incontinence: anatomic considerations at MR imaging of the paravaginal fascia and urethra initial observations.

deSouza NM, Daniels OJ, Williams AD, Gilderdale DJ, Abel PD.

Radiology. 2002 Nov;225(2):433-9.

PMID:
12409577
38.

MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis.

Kraus S, Abel PD, Nachtmann C, Linsenmann HJ, Weidner W, Stamp GW, Chaudhary KS, Mitchell SE, Franke FE, Lalani el-N.

Hum Pathol. 2002 Jan;33(1):60-7.

PMID:
11823974
39.

Urethral metastasis after transurethral resection of a malignant prostate.

Madaan S, Abel PD.

BJU Int. 2001 Aug;88(3):308. No abstract available.

40.

Human MUC1 mucin: a potent glandular morphogen.

Hudson MJ, Stamp GW, Chaudhary KS, Hewitt R, Stubbs AP, Abel PD, Lalani EN.

J Pathol. 2001 Jul;194(3):373-83.

PMID:
11439371
41.
42.

Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.

Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN.

BJU Int. 2000 Oct;86(6):736-41.

43.

Cost-benefit analysis of the use of TBT: the case for a treatment approach.

Abbott A, Abel PD, Arnold DW, Milne A.

Sci Total Environ. 2000 Aug 21;258(1-2):5-19.

PMID:
11007276
44.

TBT--towards a better way to regulate pollutants.

Abel PD.

Sci Total Environ. 2000 Aug 21;258(1-2):1-4. No abstract available.

PMID:
11007275
45.

Development of the fertility adjustment scale.

Glover L, Hunter M, Richards JM, Katz M, Abel PD.

Fertil Steril. 1999 Oct;72(4):623-8.

PMID:
10521099
46.

Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Stubbs AP, Abel PD, Golding M, Bhangal G, Wang Q, Waxman J, Stamp GW, Lalani EN.

Am J Pathol. 1999 May;154(5):1335-43.

47.

Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.

Chaudhary KS, Abel PD, Lalani EN.

Environ Health Perspect. 1999 Feb;107 Suppl 1:49-57. Review.

48.

What determines the choice of procedure in stress incontinence surgery? The use of multilevel modeling.

Griffiths JM, Black NA, Pope C, Stanley J, Bowling A, Abel PD.

Int J Technol Assess Health Care. 1998 Summer;14(3):431-45.

PMID:
9780530
49.

Impact of surgery for stress incontinence on the social lives of women.

Black NA, Bowling A, Griffiths JM, Pope C, Abel PD.

Br J Obstet Gynaecol. 1998 Jun;105(6):605-12.

PMID:
9647150
50.

Male subfertility: is pregnancy the only issue?. Psychological responses matter too-and are different in men.

Glover L, Abel PD, Gannon K.

BMJ. 1998 May 9;316(7142):1405-6. No abstract available.

Supplemental Content

Support Center